## The aetiology of anaemia during pregnancy: a study to evaluate the contribution of iron deficiency and common infections in pregnant Ugandan women

Rhona K Baingana<sup>1,\*</sup>, John K Enyaru<sup>1</sup>, Harold Tjalsma<sup>2</sup>, Dorine W Swinkels<sup>2</sup> and Lena Davidsson<sup>3</sup>

<sup>1</sup>Department of Biochemistry and Sports Science, College of Natural Sciences, Makerere University, PO Box 7062, Kampala, Uganda: <sup>2</sup>Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands: <sup>3</sup>Kuwait Institute for Scientific Research, Food and Nutrition Program, Environment and Life Sciences Research Center, Kuwait

Submitted 7 January 2014: Final revision received 27 May 2014: Accepted 29 July 2014: First published online 15 September 2014

## **Abstract**

Objective: To describe the aetiology of anaemia in pregnant Ugandan women and explore Fe deficiency and common infections as contributors to anaemia in this population.

*Design:* Cross-sectional study in which Hb, ferritin, transferrin receptor (sTfR), C-reactive protein,  $\alpha$ -1 acid glycoprotein, hepcidin, malaria, hookworm infestation, syphilis and *Helicobacter pylori* infection were assessed.

Setting: Antenatal care clinic at Kawempe Health Centre, Kampala, Uganda. Subjects: HIV-negative women  $(n\ 151)$  in their first or second pregnancy at  $10{\text -}16$  weeks' gestation.

Results: The prevalence of anaemia was 29·1%. Fe deficiency was 40·4% and 14·6% based on ferritin <30 μg/l and on adjusted ferritin <12 μg/l respectively, and 6·6% based on sTfR >8·3 μg/ml. The prevalence of Fe-deficiency anaemia was 9·3% based on ferritin <30 μg/l, 6·6% based on adjusted ferritin <12 μg/l and 4·3% based on sTfR >8·3 μg/ml. Hepcidin concentration was positively correlated with ferritin concentration (n 151, r=0·578, P<0·00001). H. pylori infection was highly prevalent (70%) while malaria, hookworm infestation and syphilis were not common. Of all women, 60·3% had α-1 acid glycoprotein >1 g/l and/or C-reactive protein >5 mg/l. Malaria parasitaemia (OR=6·85; 95% CI 1·25, 37·41, P=0·026) and Fe deficiency defined using sTfR (OR=5·58; 95% CI 1·26, 24·80, P=0·024) were independently and positively associated with anaemia. Population-attributable risk factors for anaemia for raised C-reactive protein, Fe deficiency defined by sTfR >8·3 μg/ml and presence of malaria parasites were 41·6 (95% CI 11·1, 72·2)%, 13·5 (95% CI 2·0, 25·0)% and 12·0 (95% CI 1·4, 22·6)%, respectively.

Conclusions: Infections and inflammation are of greater significance than Fe deficiency in the aetiology of anaemia in pregnant Ugandan women during the first trimester.

Keywords
Anaemia
Iron status
Pregnancy
Infection
Uganda

Nearly 25% of the world's population suffers from anaemia, with pregnant women and children of pre-school age the most affected<sup>(1)</sup>. In Uganda, anaemia is the third leading cause of in-patient mortality<sup>(2)</sup>. In 2011, 49% of under-fives, 23% of women of child-bearing age and 31% of pregnant women in Uganda had anaemia<sup>(3)</sup>. Anaemia in developing countries has a multifactorial aetiology which includes Fe deficiency (ID) due to dependence on predominantly plant-based diets from which adequate Fe cannot be absorbed<sup>(4,5)</sup>. Infections such as malaria and

hookworm infestation also contribute significantly to the high prevalence of anaemia in many settings<sup>(6)</sup>. Additionally, infection and inflammation defined by raised biomarkers contribute to anaemia as was demonstrated in a study in Malawi in which C-reactive protein (CRP) was elevated in 73·5 % of anaemic pregnant women who were Fe-replete by bone marrow assessment<sup>(7)</sup>. Hinderaker *et al.*<sup>(8)</sup> also found an association between elevated CRP and anaemia in pregnant women in rural Tanzania. More recently, *Helicobacter pylori*, the most common infection globally, has been

associated with the development of anaemia, especially in children<sup>(9,10)</sup>. Although the available evidence regarding the association between *H. pylori* infection and anaemia in pregnancy is inconclusive, it highlights the potential public health implications of *H. pylori* during pregnancy<sup>(11–14)</sup>.

Since the discovery of the main Fe regulatory hormone, hepcidin, interest has focused on the response of this hormone to both Fe status and infection<sup>(15)</sup>. Briefly, hepcidin acts by binding ferroportin and inducing its degradation, thus inhibiting cellular Fe efflux<sup>(15)</sup>. Hepcidin synthesis is reduced in ID, resulting in increased Fe absorption from the diet, while hepcidin expression is upregulated during inflammation, resulting in sequestration of Fe and thus limiting the availability of Fe for erythropoiesis<sup>(16)</sup>. The recent development of analytical methods for analysis of hepcidin in biological samples has provided an opportunity to include hepcidin as a novel biomarker reflecting Fe status.

In Uganda, pregnant women are exposed to infections such as malaria, helminths, *H. pylori* and sexually transmitted diseases. The aetiology of anaemia is largely unknown in this population. We therefore set out to describe the aetiology of anaemia in pregnant, HIV-negative Ugandan women. In particular, the aim of the study was to explore factors such as ID and common infections as contributors to anaemia during the first trimester of pregnancy in primi- or secundigravidae using biomarkers of anaemia, ID and infection and/ or inflammation.

## Participants and methods

## Study design and site

The present cross-sectional study was carried out at Kawempe Health Centre (KHC) in Kampala, the capital city of Uganda. Kampala is situated at 00°18′49″N, 32°34′52″E in south-central Uganda on the shores of Lake Victoria and at an altitude of 1200 m. Kawempe is one of five administrative divisions of Kampala District. KHC serves a densely populated, low-income area of Kampala. Malaria in this area is meso-endemic, with two peaks following the rainy seasons in March to May and September to November. The main vector is Anopheles gambiae while the common species is Plasmodium falciparum. According to the Uganda Malaria Indicator Survey of 2009<sup>(17)</sup>, the prevalence of malaria in children under 5 years of age in Kampala is 4.9 % and 7.4 % on the basis of microscopy and a rapid diagnostic test, respectively. The Uganda AIDS Indicator Survey reports that the prevalence of syphilis in pregnant women is 2.4% and is 1.8% in women of child-bearing age. (18) The median prevalence of hookworm in the Central Region of Uganda is 6.5 %<sup>(19)</sup>. The prevention and control of anaemia in pregnancy in Uganda is provided for in the National Anemia Policy<sup>(20)</sup>, which specifies the distribution of oral Fe/folic acid supplements, anthelminthics and intermittent presumptive treatment for malaria to pregnant women through antenatal care.

### Study participants

Women testing negative for HIV at booking (10–16 weeks' gestation) at the antenatal care clinic at KHC were invited to participate in the study. Inclusion criteria were: (i) first antenatal visit for the current pregnancy; (ii) Hb >7 g/dl; (iii) gestational age  $\leq$  16 weeks; (iv) primi- or secundigravida; and (v) HIV negative. Any woman with pregnancy-related complications or who reported using antibiotics in the 2 weeks preceding the sampling was excluded and referred for care at KHC.

## Data collection

After signing the consent form, socio-economic and demographic data were collected through interviews using a questionnaire. Information collected included the woman's ethnic group, age, parity, reported gestational age, educational level and employment status. Household characteristics such as household size, number of rooms, sources of water for household use, housing materials and ownership of various household assets were also assessed. Body weight was determined to the nearest 100 g using a standard clinical scale and was expressed in kilograms. Gestational age was assessed by the reported last menstrual period and examination of fundal height by experienced midwives at KHC and was expressed in weeks. The study took place from March 2009 to June 2009.

#### Laboratory tests

HIV testing was carried out as is routinely done for women attending antenatal care at health facilities in Uganda<sup>(21)</sup>. Hb was determined from finger-prick capillary blood using a HemoCue® Haemoglobinometer at the KHC laboratory following the manufacturer's directions for use. Hb values were corrected for altitude (1190 m above sea level for Kampala City) by subtracting 0.4 g/dl<sup>(22)</sup>. Results were expressed as Hb (g/dl). A rapid diagnostic test (Syphicheck-WB<sup>®</sup>; Qualpro Diagnostics, Alto Santacruz, India) was used for syphilis. Results were expressed as syphilis positive or negative. A venous blood sample (~3 ml) was drawn from each participant into Vacutainer tubes without any additives. The samples were transported in a cool box with ice packs to the Biochemistry Department, Makerere University, Kampala (~3 km away from KHC). Serum was separated by centrifugation in the Nutrition Laboratory, Biochemistry Department on the day of sampling, separated into aliquots and frozen at -20°C until analysis within 6 months. Thick smears of venous blood were prepared and stained with Giemsa for the detection of malaria parasites. Parasites were counted against 200 white blood cells by a trained laboratory technologist at KHC. Results were reported as malaria positive (irrespective of parasite density) or negative. Participants were given clean, labelled, plastic bottles with an applicator for collection of stool samples. A portion of the stool sample was examined for hookworm ova within 2 h of collection by an experienced technician at the KHC

laboratory using the saline wet mount technique and the formol-diethyl ether sedimentation technique<sup>(23)</sup>. Results were reported as positive or negative for hookworm. In addition, stool samples were transported to the Department of Biochemistry at Makerere University in Kampala on ice packs in a cool box and were analysed within 24 h for H. pylori antigens or were stored frozen (-20°C) until analysis within 7 d. H. pylori infection was determined using the Premier Platinum® Helicobacter pylori stool antigen test (Meridian Bioscience, Nivelles, Belgium), a microplate enzyme-immunoassay for the qualitative detection of H. pylori antigens in stool. The European Helicobacter pylori Study Group has recommended the use of HpSA in the initial diagnosis of H. pylori infection<sup>(24)</sup>. Results were expressed as *H. pylori* positive or negative.

Serum ferritin concentration was determined using a commercial solid-phase ELISA method (Ramco Laboratories Inc., Stafford, TX, USA). Serum transferrin receptor (sTfR) concentration was determined using a commercial enzyme immunoassay (Ramco Laboratories Inc.). Results were expressed as serum ferritin (µg/l) and serum sTfR (µg/ml), respectively. Controls provided by the manufacturer were run with each plate. Concentrations of CRP and  $\alpha$ -1 acid glycoprotein (AGP) were determined by radial immunoassay using the end-point method (Kent Laboratories Inc., Bellingham, WA, USA). The radial immunodiffusion rings were read using a digital reader (The Binding Site Ltd., Birmingham, UK). Results were expressed as serum CRP (mg/l) and serum AGP (g/l), respectively. CRP >5 mg/l and AGP >1 g/l were used as cut-offs to indicate presence of an inflammatory response to infection, according to the manufacturer. A pooled serum sample based on previously collected blood samples was run with each plate to monitor plate-to-plate and day-to-day variation.

Serum samples for hepcidin analysis were stored at -20°C at the Department of Biochemistry, Makerere University from when the first samples were collected (March 2009) until shipped to The Netherlands (April 2010). Recent hepcidin stability studies showed that hepcidin-25 concentrations in serum stored at -20°C did not change significantly for at least 6 months<sup>(25)</sup>, and seem to remain stable for a longer time (C Laarakkers and D Swinkels, unpublished results). The samples were packed on dry ice and shipped by air to the Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. Hepcidin-25 was measured in June and July 2010 by a combination of weak cation exchange chromatography and time-of-flight mass spectrometry (WCX-TOF-MS)<sup>(26)</sup>. An internal standard (synthetic hepcidin-24; Peptide International Inc., Louisville, KY, USA) was used for quantification (27). Peptide spectra were generated on a Microflex LT matrix-enhanced laser desorption/ionization (MALDI) TOF-MS platform (Bruker Daltonics, Bremen, Germany). Serum hepcidin-25 concentrations are expressed as nanomoles per litre (nmol/l). The lower limit of detection of this method was 0.5 nmol/1<sup>(26)</sup>.

#### Ethical considerations

The study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the Makerere University Faculty of Medicine Research and Ethics Committee. Written informed consent was obtained from all participants. Women diagnosed with infections (malaria, hookworm, syphilis, *H. pylori*) were referred to the health facility for care. All women recruited into the study received Fe/folic acid supplementation following the guidelines of the National Anemia Policy<sup>(20)</sup>. The study supplemented the health facility's supply of sulfadoxine-pyrimethamine, mebendazole and oral Fe/folic acid supplements.

## Data analysis

Principal components analysis was used to assign a weight to the following household assets: type of house, nature of floor and type of roof; ownership of a watch, radio, bicycle, mobile phone, land, domestic animals, a motorized vehicle and television; participant's employment status; and whether the household hired labourers. The Kaiser-Meyer-Olkin Measure of Sampling Adequacy was 0.69 while Barlett's Test of Sphericity was statistically significant, indicating significant relationships between the variables. Three components with eigenvalues higher than 1 were extracted; the first accounted for 27.5 % of the total variance and was selected as the socio-economic score. The socio-economic score was ranked and categorized into wealth tertiles (low, middle and high) with the lowest 20% in the low tertile and about 40% in the middle and high tertiles<sup>(28,29)</sup>.

Cut-offs for underweight were calculated for each week up to 16 weeks' gestation according to the approach used by Knabl et al. (30) based on the Institute of Medicine/ National Research Council guidelines. For normal-weight women, the upper cut-off of adequate gestational weight gain in the first trimester is 3 kg which results in a weekly gain of 0.23 kg in the first 13 weeks of gestation. The upper limit in the remaining 27 weeks of pregnancy is 13 kg which results in 0.48 kg/week from the 14th week onwards. The weight gain for a particular week was then calculated; for example, at week 16 this would be  $[(13 \text{ weeks} \times 0.23 \text{ kg}) +$  $(3 \text{ weeks} \times 0.48 \text{ kg})] = 4.4 \text{ kg}$ . We then used the cut-off of 45 kg to define pre-pregnancy underweight in order to derive the cut-off for underweight for a particular week. At 16 weeks this was 4.4 kg + 45 kg = 49.4 kg. A woman whose weight was less than 49.4 kg at 16 weeks of pregnancy was considered underweight.

Anaemia was defined as Hb <11 g/dl<sup>(20)</sup>. ID was defined as ferritin <12  $\mu$ g/l<sup>(32)</sup> and ferritin <30  $\mu$ g/l<sup>(33)</sup>. Additionally, ferritin values were adjusted for the effect of the acutephase response<sup>(34)</sup>. The women were first classified as normal or as having infection/inflammation on the basis of a CRP cut-off of 5 mg/l or an AGP cut-off of 1·0 g/l. A correction factor of 0·668 was obtained as the ratio of the geometric means of the ferritin concentrations of the normal

group (n 60) to the infection/inflammation group (n 91). The ferritin values of the infection/inflammation group were then multiplied by the correction factor to give the corrected ferritin values and a cut-off of ferritin <12 µg/l was used to define ID. A cut-off of sTfR > 8.3 µg/ml was also used to define ID according to the manufacturer's specification (Ramco Laboratories Inc.). Fe-deficiency anaemia (IDA) was defined as Hb <11 g/dl with ferritin  $<12 \mu g/l$ , or ferritin  $<30 \mu g/l$  or sTfR  $> 8.3 \mu g/ml$ . The ratio of sTfR to log<sub>10</sub> ferritin was also calculated. Measurements of serum hepcidin-25 that were below the limit of detection (<0.5 nmol/l) were dealt with using a goodness-of-fit approach in which values for the measurements that are below the limit of detection are selected in such a way that the Shapiro-Wilk W statistic is maximized, i.e. the 'bestfitting' normal distribution is produced<sup>(35)</sup>. Geometric mean values and 95 % confidence intervals were used to describe ferritin and hepcidin concentrations because their distributions were skewed. Spearman's correlation coefficient was used to measure the correlation between hepcidin, log<sub>10</sub> ferritin, Hb, sTfR, CRP and AGP. Pearson's  $\chi^2$  was used to evaluate associations between anaemia and background characteristics and P values < 0.05 were considered as statistically significant. Univariate logistic regression was used to assess crude associations between anaemia and the following covariates: socio-economic status, ethnic group, age, *H. pylori* status, syphilis infection, malaria infection, hookworm infestation, elevated CRP and/or AGP, Fe status and education. The risk factors associated with anaemia following univariate analysis, and *H. pylori* infection status which was of specific interest, were entered into a multivariable logistic regression to select the final set of independent risk factors for anaemia in pregnancy. We also estimated population-attributable risk (PAR) for these factors using the following formula, where *Px* is an estimate of the population exposure for case–control studies:

PAR (%) = 
$$100 \times \frac{Px(OR-1)}{1 + Px(OR-1)}$$
.

All statistical analyses were performed using the statistical software package SPSS 17-0 for Windows (2008) except for PAR% and associated 95 % confidence intervals, which were estimated using StatsDirect statistical software version 2·8·0 (2013).

#### Results

The background characteristics of the 151 mothers enrolled in the study are presented in Table 1. Mean gestational age was 13.7 (sp 2.8) weeks, mean body weight was 57.5 (sp 9.9) kg and 17.2 (95% CI 12.0, 24.1) %

**Table 1** Socio-economic and demographic characteristics of the study participants: HIV-negative women (*n* 151) in their first or second pregnancy at 10–16 weeks' gestation, attending the antenatal care clinic at Kawempe Health Centre, Kampala, Uganda, March 2009 to June 2009

	n	%	95 % CI
Age (years)			
< 20	64	42.4	34.5, 50.3
20–24	68	45⋅0	37.1, 52.9
25–29	16	10⋅6	5·7, 15·5
30+	3	2.0	0⋅5, 5⋅1
Gravidity			
Primigravida	94	62⋅3	54.3, 69.6
Secundigravida	57	37.7	30.4, 45.7
Weight status			
Normal	125	82⋅8	75.8, 88.4
Underweight	26	17⋅2	12.0, 24.1
Socio-economic status			
Lowest	26	17⋅2	11.2, 23.2
Middle	64	42.4	34.5, 50.3
High	61	40.4	32.6, 48.2
Ethnic group			
Baganda	105	69.5	62.2, 76.8
Banyankole	32	21.2	14.7, 27.7
Lugbara	8	5⋅3	2.7, 9.4
Bagisu	6	4.0	0.9, 7.1
Marital status			
Married	127	84.1	78.3, 89.9
Widowed/divorced/never married	24	15⋅9	10.1, 21.7
Education			
Primary and below	43	28.7	21.5, 35.9
Secondary and above	107	71⋅3	64.1, 78.5
Helicobacter pylori positive	106	70.2	62.9, 77.5
Syphilis positive	4	2.7	0.9, 6.0
Malaria parasites present	8	5⋅3	2.7, 9.4
Hookworm present	8	5⋅3	2.7, 9.4

**Table 2** Anaemia, iron status and indicators of infection/inflammation among HIV-negative women (*n* 151) in their first or second pregnancy at 10–16 weeks' gestation, attending the antenatal care clinic at Kawempe Health Centre, Kampala, Uganda, March 2009 to June 2009

Hb (g/dl)   Mean (sp)		Mean, % or median	SD, 95 % CI or IQR
% (95 % CI) with Hb <11 g/dl   29·1   21·9, 36·3     Ferritin (µg/l), before adjusting for infection/inflammation   61·7   66·8     Median (IQR)   38·3   19·5-75·5     Geometric mean (95 % CI)   39·9   51·1, 14·7     % (95 % CI) with ferritin <12 µg/l   99·9   51·1, 14·7     % (95 % CI) with ferritin <30 µg/l   40·4   32·9, 48·4     Ferritin (µg/l), after adjusting for infection/inflammation   26·8, 35·9     % (95 % CI) with ferritin <12 µg/l   14·6   9·7, 21·1     STIR (µg/ml)   20·1   20·1   20·1     Mean (so)   5.5   2.0     Median (IQR)   5.0   42-6·4     % (95 % CI) with sTIR >8·3 µg/ml   6·6   36·, 11·0     STIR-ferritin index   31·4   2·53-4·27     Mean (so)   3.75   2.32     Median (IQR)   3.14   2·53-4·27     AGP (g/l)   40·6   0.55-0·77     % (95 % CI) with AGP >1 g/l   0.66   0.55-0·77     % (95 % CI) with AGP >1 g/l   0.5     Median (IQR)   3.14   2.52     Median (IQR)   3.14   2.53     Median (IQR)   3.14   3.14     Mean (so)   3.14   3.14     Mean (so)   3.14   3.14     Median (IQR)   3.14     Median (IQR)   3.14   3.14     Median (IQR)   3.14     Medi	Hb (g/dl)		
Ferritin (μg/l), before adjusting for infection/inflammation   Mean (sb)   66.8   Median (IQR)   38.3   19.5-75.5   Geometric mean (95% CI)   39.6   34.1, 46.0   38.3   39.6   34.1, 46.0   39.6   34.1, 46.0   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4		11.8	1.7
Ferritin (μg/l), before adjusting for infection/inflammation   Mean (sb)   66.8   Median (IQR)   38.3   19.5-75.5   Geometric mean (95% CI)   39.6   34.1, 46.0   38.3   39.6   34.1, 46.0   39.6   34.1, 46.0   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4   32.9, 48.4   40.4	% (95 % CI) with Hb <11 g/dl	29.1	21.9, 36.3
Mean (Sp)			•
Geometric mean (95 % Cl)         39-6         34-1, 46-0           % (95 % Cl) with ferritin <12 μg/l	" O / '	61.7	66⋅8
Geometric mean (95 % Cl)         39-6         34-1, 46-0           % (95 % Cl) with ferritin <12 μg/l	Median (ÍQR)	38.3	19.5–75.5
% (95 % Cl) with ferritin <30 μg/l		39.6	
% (95 % Cl) with ferritin <30 μg/l	% (95 % CI) with ferritin <12 ug/l	9.9	5.1. 14.7
Ferritin (μg/l), after adjusting for infection/inflammation           Geometric mean (95 % Cl)         31·0         26·8, 35·9           % (95 % Cl) with ferritin <12 μg/l			•
Geometric mean (95 % Cl)       31.0       26.8, 35.9         % (95 % Cl) with ferritin <12 μg/l	( )		, -
		31.0	26.8. 35.9
STfR (μg/ml)       S-5       2.0         Median (IQR)       5-0       4.2–6.4         % (95% CI) with sTfR >8·3 μg/ml       6-6       3-6, 11.0         STfR-ferritin index       Mean (sp)       3.75       2.32         Median (IQR)       3-14       2.53–4-27         AGP (g/l)       Median (IQR)       0.70       0.23         Median (IQR)       9-9       5-1, 14-7         CRP (mg/l)*       Median (IQR)       22-1       25-2         Median (IQR)       15-5       11.7–20-8         Geometric mean (95 % CI)       15-0       12-3, 18-3         % (95 % CI) with CRP >5 mg/l       58-9       51-1, 66-8         % (95 % CI) with infection/inflammation†       60-3       52-5, 68-1         Hepcidin-25 (nmol/l)       Mean (sp)‡       1.4       2.1         Median (IQR)‡       0.4       0.2–1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sp)§       3-0       2.4         Median (IQR)§       1.9       1.3–4-4			•
Mean (sp)       5.5       2.0         Median (IQR)       5.0       4.2-6.4         % (95 % CI) with sTfR >8.3 μg/ml       6.6       3.6, 11.0         sTRH-ferritin index         Mean (sp)       3.75       2.32         Median (IQR)       3.14       2.53-4.27         AGP (g/l)       8       8.25         Mean (sp)       0.66       0.55-0.77         % (95 % CI) with AGP >1 g/l       9.9       5.1, 14.7         CRP (mg/l)*       22.1       25.2         Median (IQR)       15.5       11.7-20.8         Geometric mean (95 % CI)       15.0       12.3, 18.3         % (95 % CI) with Infection/inflammation†       60.3       52.5, 68.1         Hepcidin-25 (nmol/l)       1.4       2.1         Mean (sp)‡       1.4       2.1         Median (IQR)‡       0.4       0.2-1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sp)§       3.0       2.4         Median (IQR)§       1.9       1.3-4.4			
Median (IQR)       5·0       4·2–6·4         % (95 % CI) with sTfR >8·3 μg/ml       6·6       3·6, 11·0         STR—ferritin index       Wean (sp)       3·75       2·32         Median (IQR)       3·14       2·53–4·27         AGP (g/l)       Median (sp)       0.70       0·23         Median (IQR)       0·66       0·55–0·77         % (95 % CI) with AGP >1 g/l       9·9       5·1, 14·7         CRP (mg/l)*       Mean (sp)       22·1       25·2         Median (IQR)       15·5       11·7–20·8         Geometric mean (95 % CI)       15·0       12·3, 18·3         % (95 % CI) with CRP >5 mg/l       58·9       5·1·1, 6·8         % (95 % CI) with infection/inflammation†       60·3       5·2·5, 6·8·1         Hepcidin-25 (nmol/l)       Mean (sp)‡       1·4       2·1         Median (IQR)‡       0·4       0·2–1·7         Geometric mean (95 % CI)‡       0·5       0·4, 0·7         Mean (sp)§       3·0       2·4         Median (IQR)§       1·9       1·3–4·4		5.5	2.0
% (95 % CI) with sTfR >8.3 μg/ml       6.6       3.6, 11.0         sTfR—ferritin index       3.75       2.32         Median (IQR)       3.14       2.53–4.27         AGP (g/l)       8.0       0.70       0.23         Median (IQR)       0.66       0.55–0.77       0.99       5.1, 14.7         CRP (mg/l)*       9.9       5.1, 14.7       CRP (mg/l)*         Mean (sD)       22.1       25.2         Median (IQR)       15.5       11.7–20.8         Geometric mean (95 % CI)       15.0       12.3, 18.3         % (95 % CI) with infection/inflammation†       58.9       51.1, 66.8         % (95 % CI) with infection/inflammation†       60.3       52.5, 68.1         Hepcidin-25 (nrmol/l)       1.4       2.1         Median (IQR)‡       0.4       0.2–1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sD)§       3.0       2.4         Median (IQR)§       1.9       1.3–4.4			
sTfR–ferritin index       3.75       2.32         Median (IQR)       3.14       2.53–4.27         AGP (g/l)       0.70       0.23         Mean (sD)       0.66       0.55–0.77         % (95 % CI) with AGP >1 g/l       9.9       5.1, 14.7         CRP (mg/l)*       22.1       25.2         Median (IQR)       15.5       11.7–20.8         Geometric mean (95 % CI)       15.0       12.3, 18.3         % (95 % CI) with CRP >5 mg/l       58.9       51.1, 66.8         % (95 % CI) with infection/inflammation†       60.3       52.5, 68.1         Hepcidin-25 (nmol/l)       1.4       2.1         Median (IQR)‡       0.4       0.2–1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sD)§       3.0       2.4         Median (IQR)§       1.9       1.3–4.4			_
Mean (sD)       3.75       2.32         Median (IQR)       3.14       2.53-4.27         AGP (g/I)           Mean (sD)       0.70       0.23         Median (IQR)       0.66       0.55-0.77         % (95 % CI) with AGP >1 g/I       9.9       5.1, 14.7         CRP (mg/I)*       Mean (sD)       22.1       25.2         Median (IQR)       15.5       11.7-20.8         Geometric mean (95 % CI)       15.0       12.3, 18.3         % (95 % CI) with infection/inflammation†       60.3       51.1, 66.8         % (95 % CI) with infection/inflammation†       60.3       52.5, 68.1         Hepcidin-25 (nmol/I)       Mean (sD)‡       0.4       0.2-1.7         Geometric mean (95 % CI)‡       0.4       0.2-1.7         Median (IQR)‡       0.5       0.4, 0.7         Mean (sD)\$       3.0       2.4         Median (IQR)\$       1.9       1.3-4.4		• •	2 2, 11 2
Median (IQR)       3·14       2·53-4·27         AGP (g/l)       0.70       0.23         Median (IQR)       0.66       0.55-0·77         % (95% CI) with AGP >1 g/l       9.9       5·1, 14·7         CRP (mg/l)*       **         Mean (sD)       22·1       25·2         Median (IQR)       15·5       11·7-20·8         Geometric mean (95% CI)       15·0       12·3, 18·3         % (95% CI) with CRP >5 mg/l       58·9       51·1, 66·8         % (95% CI) with infection/inflammation†       60·3       52·5, 68·1         Hepcidin-25 (nmol/l)       **       2·1         Median (IQR)‡       0·4       0·2-1·7         Geometric mean (95% CI)‡       0·5       0·4, 0·7         Mean (sD)§       3·0       2·4         Median (IQR)§       1·9       1·3-4·4		3.75	2.32
AGP (g/l)  Mean (sp)		3.14	2.53-4.27
Mean (sD)       0.70       0.23         Median (IQR)       0.66       0.55–0.77         % (95 % CI) with AGP >1 g/l       9.9       5.1, 14-7         CRP (mg/l)*       Mean (sD)       22.1       25.2         Median (IQR)       15.5       11.7–20.8         Geometric mean (95 % CI)       15.0       12.3, 18.3         % (95 % CI) with CRP >5 mg/l       58.9       51.1, 66.8         % (95 % CI) with infection/inflammation†       60.3       52.5, 68.1         Hepcidin-25 (nmol/l)       Mean (sD)‡       1.4       2.1         Median (IQR)‡       0.4       0.2–1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sD)§       3.0       2.4         Median (IQR)§       1.9       1.3–4.4		-	
Median (IQR)       0.66       0.55−0.77         % (95 % CI) with AGP >1 g/l       9.9       5.1, 14.7         CRP (mg/l)*       Mean (sD)       22.1       25.2         Median (IQR)       15.5       11.7−20.8         Geometric mean (95 % CI)       15.0       12.3, 18.3         % (95 % CI) with CRP >5 mg/l       58.9       51.1, 66.8         % (95 % CI) with infection/inflammation†       60.3       52.5, 68.1         Hepcidin-25 (nmol/l)       Mean (sD)‡       1.4       2.1         Median (IQR)‡       0.4       0.2−1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sD)§       3.0       2.4         Median (IQR)§       1.9       1.3−4.4		0.70	0.23
% (95 % CI) with AGP >1 g/l       9.9       5.1, 14.7         CRP (mg/l)*       22.1       25.2         Median (IQR)       15.5       11.7–20.8         Geometric mean (95 % CI)       15.0       12.3, 18.3         % (95 % CI) with CRP >5 mg/l       58.9       51.1, 66.8         % (95 % CI) with infection/inflammation†       60.3       52.5, 68.1         Hepcidin-25 (nmol/l)       1.4       2.1         Mean (sD)‡       0.4       0.2–1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sD)§       3.0       2.4         Median (IQR)§       1.9       1.3–4.4	` /	0.66	
CRP (mg/l)*  Mean (sD)  Median (IQR)  Geometric mean (95 % CI)  (95 % CI) with CRP >5 mg/l  (95 % CI) with infection/inflammation†  Hepcidin-25 (nmol/l)  Mean (sD)‡  Median (IQR)‡  Geometric mean (95 % CI)  15·0  15·0  15·0  16·3  16·8  51·1, 66·8  60·3  52·5, 68·1  Hepcidin-25 (nmol/l)  Mean (sD)‡  Median (IQR)‡  Geometric mean (95 % CI)‡  Mean (sD)§  Median (IQR)§  1·9  1·3-4·4		9.9	5.1. 14.7
Mean (sD)       22·1       25·2         Median (IQR)       15·5       11·7-20·8         Geometric mean (95 % CI)       15·0       12·3, 18·3         % (95 % CI) with CRP >5 mg/l       58·9       51·1, 66·8         % (95 % CI) with infection/inflammation†       60·3       52·5, 68·1         Hepcidin-25 (nmol/l)       1·4       2·1         Mean (sD)‡       0·4       0·2-1·7         Geometric mean (95 % CI)‡       0·5       0·4, 0·7         Mean (sD)§       3·0       2·4         Median (IQR)§       1·9       1·3-4·4	` ,		- ,
Median (IQR)       15.5       11.7–20.8         Geometric mean (95 % CI)       15.0       12.3, 18.3         % (95 % CI) with CRP >5 mg/l       58.9       51.1, 66.8         % (95 % CI) with infection/inflammation†       60.3       52.5, 68.1         Hepcidin-25 (nmol/l)       1.4       2.1         Mean (sD)‡       0.4       0.2–1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sD)§       3.0       2.4         Median (IQR)§       1.9       1.3–4.4		22.1	25.2
Geometric mean (95 % CI)       15·0       12·3, 18·3         % (95 % CI) with CRP >5 mg/l       58·9       51·1, 66·8         % (95 % CI) with infection/inflammation†       60·3       52·5, 68·1         Hepcidin-25 (nmol/l)       Mean (sD)‡       1·4       2·1         Median (IQR)‡       0·4       0·2-1·7         Geometric mean (95 % CI)‡       0·5       0·4, 0·7         Mean (sD)§       3·0       2·4         Median (IQR)§       1·9       1·3-4·4	` /	15⋅5	
% (95 % CI) with CRP >5 mg/l       58.9       51.1, 66.8         % (95 % CI) with infection/inflammation†       60.3       52.5, 68.1         Hepcidin-25 (nmol/l)			
% (95 % CI) with infection/inflammation†       60·3       52·5, 68·1         Hepcidin-25 (nmol/I)       1·4       2·1         Mean (sD)‡       0·4       0·2–1·7         Geometric mean (95 % CI)‡       0·5       0·4, 0·7         Mean (sD)§       3·0       2·4         Median (IQR)§       1·9       1·3–4·4			•
Hepcidin-25 (nmol/l)       1.4       2.1         Mean (sp)‡       0.4       0.2–1.7         Median (IQR)‡       0.5       0.4, 0.7         Mean (sp)§       3.0       2.4         Median (IQR)§       1.9       1.3–4.4			•
Mean (sp)‡       1.4       2.1         Median (IQR)‡       0.4       0.2–1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sp)§       3.0       2.4         Median (IQR)§       1.9       1.3–4.4	•		5-5, 55
Median (IQR)‡       0.4       0.2–1.7         Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sD)§       3.0       2.4         Median (IQR)§       1.9       1.3–4.4		1.4	2.1
Geometric mean (95 % CI)‡       0.5       0.4, 0.7         Mean (sb)§       3.0       2.4         Median (IQR)§       1.9       1.3-4.4			
Mean (sp)§       3.0       2.4         Median (IQR)§       1.9       1.3-4.4			
Median (IQR)§ 1.3–4.4			
	Geometric mean (95 % CI)§	2.3	1.9, 2.8

IQR, interquartile range; sTfR, serum transferrin receptor; AGP, α-1 acid glycoprotein; CRP, C-reactive protein.

were underweight. Most women were young (over 80% were under 25 years), two-thirds were primigravidae and a large majority were married. About 70% had attained secondary education or higher. Almost 70% of the women were Baganda, which is the main ethnic group in the central region where Kampala City is located. The prevalence of *H. pylori* infection was 70·2 (95% CI 62·9, 77·5)%. Four women tested positive for syphilis; eight women tested positive for malaria parasites and for hookworm ova, respectively.

## Anaemia and Fe status

Mean Hb was 11·8 (sp 1·7) g/dl and the prevalence of anaemia was 29·1 (95 % CI 21·9, 36·3) %. Geometric mean ferritin concentration was 39·6 (95 % CI 34·1, 46·0)  $\mu$ g/l (Table 2) and 9·9 (95 % CI 5·1, 14·7) % of women had ferritin <12  $\mu$ g/l. When a higher ferritin cut-off (<30  $\mu$ g/l) based on previous recommendations for anaemic pregnant African women<sup>(33)</sup> was used, the prevalence of ID

was 40.4~(95~%~CI~32.9,~48.4) %. The prevalence of ID was 14.6~(95~%~CI~9.7,~21.1) % following adjustment of ferritin values for infection/inflammation. Median sTfR was  $5.0~(interquartile~range~(IQR)~4.2-6.4)~\mu g/ml~and~6.6~(95~\%~CI~3.6,~11.0)$  % of women had serum sTfR >8.3  $\mu$ g/ml. Median sTfR-ferritin index was 3.14~(IQR~2.5-4.3). Figure 1 shows that 24.5~% of the women had anaemia without ID based on sTfR >8.3  $\mu$ g/ml while 19.9~% had anaemia without ID based on serum ferritin <30  $\mu$ g/l and 22.5~% had anaemia without ID based on adjusted serum ferritin <12  $\mu$ g/l. The prevalence of IDA was 4.6~% based on sTfR >8.3  $\mu$ g/ml, 9.3~% based on serum ferritin <30  $\mu$ g/l and 6.6~% based on adjusted serum ferritin <12  $\mu$ g/l.

# Anaemia, Fe status and markers of the acute response to infections

Mean AGP was 0.7 (sp 0.23) g/l and 9.9 (95 % CI 5.1, 14.7) % of the women had AGP >1 g/l (Table 2). Mean CRP was markedly raised (22.1 (sp 25.2) mg/l) and 58.9 (95 % CI

<sup>\*</sup>Only for those with CRP above the lower effective assay level (n 93).

<sup>†</sup>AGP and/or CRP greater than 1 g/l and 5 mg/l, respectively.

<sup>‡</sup>Values for the measurements of serum hepcidin-25 that were below the limit of detection (<0.5 nmol/l, n 90) were selected using the method described by Flynn<sup>(35)</sup>.

<sup>§</sup>Only for those with hepcidin  $\geq 0.5$  nmol/l (n 61).





Fig. 1 The distribution of anaemia (□), anaemia without iron deficiency (ID; □), ID with anaemia (iron-deficiency anaemia; □), ID without anaemia (□) and ID (with and without anaemia; □) in the study participants on the basis of the indicated biomarkers and cut-offs to define ID. HIV-negative women (*n* 151) in their first or second pregnancy at 10–16 weeks' gestation, attending the antenatal care clinic at Kawempe Health Centre, Kampala, Uganda, March 2009 to June 2009 (sTfR, serum transferrin receptor)



**Fig. 2** The distribution of iron deficiency (ID) defined with the indicated cut-offs and biomarkers, and infection/inflammation status ( $\blacksquare$ ), according to anaemia presence: no ID, normal CRP and AGP (CRP ≤ 5 mg/l and AGP ≤ 1 g/l  $\equiv$ ); no ID, elevated CRP and/or AGP ( $\square$ ); ID, normal CRP and AGP ( $\square$ ); ID, elevated CRP and/or AGP ( $\square$ ). HIV-negative women (n 151; anaemic n 44; non-anaemic n 107) in their first or second pregnancy at 10–16 weeks' gestation, attending the antenatal care clinic at Kawempe Health Centre, Kampala, Uganda, March 2009 to June 2009 (sTfR, serum transferrin receptor; CRP, C-reactive protein; AGP, α-1 acid glycoprotein)

51·1, 66·8) % had CRP >5 mg/l. In total, 60·3 (95 % CI 52·5, 68·1) % of the women had elevated AGP and/or CRP concentrations. Figure 2 shows that of the women with anaemia and those without anaemia respectively, 72·7 % and 55·1 % had raised CRP and/or AGP concentrations. The prevalence of raised CRP and/or AGP in the women with non-ID anaemia was 50·0 %, 61·4 % and 56·8 % when ID was defined using ferritin <30  $\mu$ g/l, sTfR >8·3  $\mu$ g/ml and adjusted ferritin <12  $\mu$ g/l, respectively.

The concentration of hepcidin in ninety (59.6%) samples was below the limit of detection (<0.05 nmol/l). After selecting

values for measurements of serum hepcidin that were below the limit of detection using the method described by Flynn<sup>(35)</sup>, geometric mean hepcidin concentration was 0.5 (95% CI 0.4, 0.7) nmol/l for all samples and 2.3 (95% CI 1.9, 2.8) nmol/l for the samples that were above the limit of detection (n 61). Hepcidin concentration was positively correlated with ferritin concentration (n 151, r=0.578, P<0.00001; Table 3) and negatively correlated with the sTfR–ferritin index (n 151, r=0.298, P=0.0001). Ferritin concentration was positively correlated with AGP (n 151, r=0.299, P=0.0001) and negatively correlated with sTfR

**Table 3** Pairwise correlations between Hb, ferritin, sTfR, AGP, CRP and hepcidin among HIV-negative women (*n* 151) in their first or second pregnancy at 10–16 weeks' gestation, attending the antenatal care clinic at Kawempe Health Centre, Kampala, Uganda, March 2009 to June 2009

	Log Hb	Log ferritin	Log sTfR	Log AGP	Log CRP*	Log hepcidin†	Log TF index
Log Hb Log ferritin log sTfR Log AGP Log CRP* Log hepcidin† Log TF index	1.000 - 0.047 - 0.283 - 0.184 <sup>b</sup> - 0.113 0.032 - 0.249 <sup>c</sup>	1.000 - 0.162 <sup>a</sup> 0.299 <sup>f</sup> 0.165 0.578 <sup>g</sup> - 0.569 <sup>g</sup>	1.000 0.072 0.247° - 0.064 0.756 <sup>9</sup>	1.000 0.333 <sup>d</sup> 0.134 - 0.095	1·000 0·023 0·104	1.000 – 0.298 <sup>†</sup>	1.000

sTfR, serum transferrin receptor; AGP, α-1 acid glycoprotein; CRP, C-reactive protein; TF index, serum transferrin receptor–ferritin index. \*Only for those with CRP above the lower effective assay level (*n* 93).

(n 151, r=-0.162, P=0.02) and sTfR-ferritin index (n 151, r=-0.569, P<0.00001). Hb was negatively correlated with AGP (n 151, r=-0.184, P=0.011) and with the sTfR-ferritin index (n 151, r=-0.249, P=0.001). The difference in mean hepcidin concentration between women with and without ID defined by the different ferritin cut-offs respectively was significant, with a higher mean hepcidin concentration among women with adequate Fe stores (data not shown).

## Anaemia, malaria, hookworm, H. pylori infection and other factors

Mothers in the 25–29 years age group had slightly lower odds of anaemia (OR = 0·12; 95 % CI 0·02, 0·96, P = 0·048) relative to mothers in the <20 years age group (Table 4). The odds of anaemia were eight times higher among women with malaria parasites relative to women without malaria parasites (OR = 8·29; 95 % CI 1·60, 42·85; P = 0·012). Women with raised CRP and/or AGP had higher odds of anaemia relative to women with normal CRP and/or AGP, respectively. Women with ID defined using sTfR >8·3 µg/ml had higher odds of anaemia compared with women without ID (OR = 6·56; 95 % CI 1·61, 26·69, P = 0·009).

Multivariate analysis showed that the presence of malaria parasites was independently and positively associated with anaemia irrespective of the biomarker used to define ID (Table 5). ID defined using sTfR >8·3  $\mu$ g/ml (OR = 5·58; 95 % CI 1·26, 24·80) and adjusted ferritin <12  $\mu$ g/l (OR = 2·86; 95 % CI 1·08, 7·52) was independently and positively associated with anaemia, while the presence of hookworm was independently and positively associated with anaemia only when adjusted ferritin was used as a biomarker for ID (OR = 6·08; 95 % CI 1·32, 27·93). Table 5 shows that raised CRP had the largest PAR for anaemia (41·6 %; 95 % CI 1·1, 72·2 %) followed by ID defined by sTfR >8·3  $\mu$ g/ml (13·5 %; 95 % CI 2·0, 25·0 %) and malaria (12·0 %; 95 % CI 1·4, 22·6 %).

## Discussion

As expected, anaemia, infections and/or inflammation were common in this study population. The prevalence of anaemia was 29·1 % which is comparable to 31 % reported

in the Uganda Demographic and Health Survey 2011<sup>(3)</sup> and is consistent with data from other studies in Uganda<sup>(36-39)</sup>. However, IDA represented only a small proportion of all anaemia, about 5-10% depending on the biomarker used and cut-off level applied. Also as expected, ferritin values were widely dispersed and the distribution was skewed to the right. When ID was defined with the commonly used cut-off ( $<12 \mu g/l$ ) the prevalence of ID was 9.9 %. When a higher cut-off was used,  $<30 \,\mu\text{g/l}$ , based on Van den Broek et al.'s study of anaemic, pregnant Malawian women using the gold standard bone marrow smear test to define Fe status (33), the prevalence of ID was 40.4%. A previous study in Masindi in western Uganda reported similar findings, as the prevalence of ID among primi- and secundigravidae was 27.3 % based on 30 µg/l as the ferritin cut-off for ID<sup>(36)</sup>. Our second measure of Fe status was sTfR, which is a specific and sensitive marker of Fe deficiency in pregnancy at the cut-off recommended by the manufacturer  $^{(40)}$ . Given that available commercial immunoassays for sTfR are not standardized<sup>(41)</sup>, it is only possible to compare sTfR concentrations across studies that have used the same commercial kit. Mean sTfR concentration obtained in the current study compares well with findings from studies that have used the Ramco sTfR kit (42-45). Serum sTfR concentration does not appear to be affected by infectious or inflammatory conditions (46) except for malaria, which in some studies has been observed to increase sTfR levels (47-49) while in at least one other study caused a decrease in sTfR<sup>(50)</sup>. We did not find any difference in sTfR levels by malaria status or by infection/ inflammation (data not shown). ID defined using sTfR and using adjusted ferritin was independently associated with anaemia in pregnancy.

Median hepcidin concentration in our study population was lower than what van Santen *et al.*<sup>(51)</sup> found in the first trimester in a longitudinal study of thirty-one healthy pregnant women in The Netherlands with normal haematological blood counts. Of note, the hepcidin concentrations in their study decreased to undetectable levels in the third trimester, and this was paralleled by decreasing Hb. Given that mean Hb was lower in our study and that nearly a third of the women had anaemia, it is not unexpected that median

<sup>†</sup>Values for the measurements of serum hepcidin-25 that were below the limit of detection (<0.5 nmol/l, n 90) were selected using the method described by Flynn<sup>(35)</sup>. One-tailed significance levels:  ${}^{a}P = 0.02$ ,  ${}^{b}P = 0.011$ ,  ${}^{c}P = 0.001$ ,  ${}^{d}P = 0.006$ ,  ${}^{e}P = 0.008$ ,  ${}^{f}P = 0.0001$ ,  ${}^{g}P < 0.00001$ .

Table 4 Univariate analysis for association between maternal characteristics and anaemia among HIV-negative women (n 151) in their first or second pregnancy at 10–16 weeks' gestation, attending the antenatal care clinic at Kawempe Health Centre, Kampala, Uganda, March 2009 to June 2009

	Anaemia (Hb <11 g/dl)						Univariate		
Characteristic	N	n	%	95 % CI	$\chi^2$	Р	OR	95 % CI	P
Age (years)									
<20	64	23	35.9	24.1, 47.7			1.00	Ref.	
20–24	68	19	27.9	17.2, 38.6			0.69	0.33, 1.44	0.325
25–29	16	1	6.3	0.3, 26.5			0.12	0.02, 0.96	0.048
30+	3	1	33.3	1.7, 86.5	5.57	0.135	0.89	0.08, 10.37	0.927
Gravidity									
Primigravida	94	29	30.9	22.4, 40.8			1.00	Ref.	
Secundigravida	57	15	26.3	16.6, 39.1	0.35	0.552	0.80	0.38, 1.67	0.553
Weight status									
Normal	125	37	29.6	22.3, 38.1			1.00	Ref.	
Underweight	26	7	26.9	13.5, 46.3	0.08	0.785	0.88	0⋅34, 2⋅26	0.785
Socio-economic status									
Lowest	26	9	34.6	16.3, 52.9			1.00	Ref.	
Middle	64	21	32.8	21.3, 44.3			0.92	0.35, 2.41	0.869
High	61	14	23.0	12.4, 33.6	1.93	0.382	0.56	0.21, 1.54	0.262
Ethnic group									
Baganda	105	30	28.6	20.0, 37.2			1.00	Ref.	
Banyankole	32	8	25.0	10.0, 40.0			0.83	0.34, 2.06	0.693
Lugbara	8	4	50.0	19.3, 80.7			2.50	0.59, 10.65	0.215
Bagisu	6	2	33.3	6.3, 72.8	2.02	0.568	1.25	0.22, 7.19	0.803
Marital status									
Married	127	35	37⋅5	18.1, 56.9			1.00	Ref.	
Widowed/divorced/never married	24	9	27.6	19.8, 35.4	0.97	0.326	1.58	0.63, 3.93	0.328
Education									
Primary and below	43	12	27.9	14.5, 41.3			1.00	Ref.	
Secondary and above	107	32	29.9	21.2, 38.6	0.06	0.808	1.10	0.50, 2.42	0.808
Helicobacter pylori status								<b>-</b> .	
Negative	45	12	26.7	13.8, 39.6	0.40		1.00	Ref.	0.000
Positive	106	32	30⋅2	21.5, 38.9	0.19	0.663	1.19	0.55, 2.59	0.663
Syphilis status	4.45	40	00.0	04.0.00.4			4.00	D - (	
Negative	145	42	29.0	21.6, 36.4	0.00	0.000	1.00	Ref.	0.00
Positive	4	1	25.0	1.3, 75.1	0.03	0.863	0.82	0.08, 8.08	0⋅86
Malaria status	4.40	00	00.0	10.4.00.0			4.00	D - (	
No parasites	143	38	26.6	19.4, 33.8	0.04	0.000	1.00	Ref.	0.040
Parasites present	8	6	75⋅0	40.0, 95.4	8.61	0.003	8.29	1.60, 42.85	0.012
Hookworm	100	00	07.0	100 017			1.00	Def	
No parasites	139	38	27.3	19.9, 34.7	4.50	0.004	1.00	Ref.	0.040
Parasites present	8	5	62.5	29.0, 88.9	4.52	0.034	4.43	1.01, 19.44	0.049
AGP status	100	20	00.7	011 060			1.00	Dof	
Normal (≤1.0 g/l)	136	39	28.7	21.1, 36.3	0.14	0.706	1.00	Ref.	0.707
Raised (>1·0 g/l)	15	5	33.3	14.2, 57.7	0.14	0.706	1.24	0.40, 3.87	0.707
CRP status	00	40	10.4	11 0 01 0			1.00	Def	
Normal (≤5.0 mg/l)	62	12	19.4	11.3, 31.0	4.07	0.007	1.00	Ref.	0.000
Raised (>5·0 mg/l)	89	32	36.0	26.7, 46.3	4.87	0.027	2.34	1.09, 5.02	0.029
Infection/inflammation*	00	40	00.0	0.0.00.1			1.00	Def	
Not present	60	12	20.0	9.9, 30.1	4.00	0.045	1.00	Ref.	0.047
Present	91	32	35.2	25.4, 45.0	4.03	0.045	2.17	1.01, 4.66	0.047
Fe status STfR									
	141	27	26.2	18.9, 33.5			1.00	Ref.	
≤8·3 μg/ml (no ID)	10	37 7	70·2	31.4, 91.2	8.66	0.003	6·56	1.61, 26.69	0.009
>8⋅3 μg/ml (ID) Ferritin (unadjusted)†	10	,	70.0	31.4, 91.2	0.00	0.003	0.30	1.01, 20.09	0.009
≥12 μg/l (no ID)	126	37	27.2	10.7 247			1.00	Ref.	
,	136			19.7, 34.7	2 40	0 115			0.123
<12 μg/l (ID)	15	7	46.7	24.4, 69.9	2.48	0.115	2.43	0·79, 6·91	0.123
≥30 µg/l (no ID)	90	30	33.3	25.7, 41.9	1.00	0.160	1.00	Ref.	0.170
<30 µg/l (ID)	61	14	23.0	15.3, 32.9	1.90	0.168	0.60	0.29, 1.25	0.173
Ferritin (adjusted)†	100	24	26.4	105 246			1.00	Dof	
≥12 µg/l (no ID)	129	34	26·4	19.5, 34.6	2 20	0.060	1.00	Ref.	0.074
<12 μg/l (ID)	22	10	45⋅5	26.9, 65.4	3.32	0.068	2.33	0.92, 5.88	0.074

N, number of women in the category, n, number of women in that category who have anaemia; AGP, α-1 acid glycoprotein; CRP, C-reactive protein; sTfR, serum transferrin receptor; ID, iron deficiency; Ref., reference category.
\*Infection/inflammation present when AGP and/or CRP is/are raised.
†Adjusted for infection/inflammation.

Table 5 Multivariate analysis for factors associated with anaemia at 10–16 weeks of pregnancy in HIV-negative women attending the antenatal care clinic at Kawempe Health Centre, Kampala, Uganda, March 2009 to June 2009 (n 151) and their population-attributable risk

Factor	OR†	95 % CI	P	OR‡	95 % CI	P	PAR%	95 % CI
H. pylori status								
Negative	1.00	Ref.		1.00	Ref.			
Positive	1.20	0.50, 2.89	0.679	1.04	0.45, 2.44	0.920	11.6	– 37·9, 61·1
Malaria status		·						•
No parasites	1.00	Ref.		1.00	Ref.			
Parasites present	6.85	1.25, 37.41	0.026	8.71	1.61, 47.26	0.012	12.0	1.4, 22.6
Hookworm								
No parasites	1.00	Ref.		1.00	Ref.			
Parasites present	4.52	0.93, 22.0	0.062	6.08	1.32, 27.93	0.020	9.0	– 1⋅3, 19⋅3
CRP status								
Normal (≤5.0 mg/l)	1.00	Ref.		1.00	Ref.			
Raised (>5.0 mg/l)	1.98	0.86, 4.54	0.109	1.98	0.86, 4.54	0.106	41.6	11.1, 72.2
Fe status using sTfR >8	3⋅3 µg/ml							
No ID	1.00	Ref.						
ID present	5.58	1.26, 24.80	0.024				13⋅5	2.0, 25.0
Fe status using adjusted	d* ferritin <1	2 μg/l						
No ID		· -		1.00	Ref.			
ID present				2.86	1.08, 7.52	0.034	13.0	− 2·2, 28·1

PAR, population-attributable risk; CRP, C-reactive protein; sTfR, serum transferrin receptor; ID, iron deficiency; Ref., reference category. \*Adjusted for infection/inflammation.

hepcidin concentration is also lower. Median hepcidin concentrations in both studies were lower than the reference values from non-pregnant, non-anaemic women without infection and/or inflammation, defined as CRP  $<10 \text{ mg/l}^{(52)}$ . A subset of this reference study population, without ID (ferritin >30 µg/l), had an even higher serum hepcidin level. The production of hepcidin is regulated by Fe, with hepcidin synthesis being suppressed during ID, thus allowing more Fe to enter plasma<sup>(16)</sup>. Hepcidin production is also suppressed during active erythropoiesis, making more Fe available for Hb synthesis<sup>(16)</sup>. Thus, the substantially lower hepcidin concentration we found reflects active erythropoiesis and the increased demand for Fe during pregnancy. Moreover, mean hepcidin was significantly lower among women with ID compared with women with adequate Fe stores when ID was defined using either ferritin cut-off even though ferritin concentrations were raised apparently due to infection/ inflammation and not necessarily because Fe stores were adequate. This seems to suggest that in pregnancy, the need for Fe overrides the normal response of hepcidin to infection/inflammation which causes an increase in hepcidin (16). Hepcidin had a significant positive correlation with ferritin and a significant negative correlation with the sTfR-ferritin index, and was not correlated with CRP and sTfR in the present study. Similar findings were obtained in pregnant women in Bangladesh<sup>(45)</sup> and in healthy pregnant women in The Netherlands<sup>(51)</sup>. In contrast, a study of Turkish pregnant women did not find any relationship between hepcidin and ferritin<sup>(53)</sup>. Given that serum ferritin is recognized as the most important correlate of serum hepcidin concentration<sup>(52)</sup>, the latter results can be ascribed to limitations in the commercial assav used<sup>(54)</sup>.

Mean CRP concentration was markedly raised and nearly two-thirds of the women had elevated CRP, defined as

>5 mg/l. A high prevalence of infection and/or inflammation, indicated by elevated CRP, was also reported among 150 anaemic pregnant women in Malawi as mean CRP concentration was 30 mg/l and 35 % had elevated CRP (CRP >190 nmol/l (19.5 mg/l))<sup>(7)</sup>. Although CRP increases during normal pregnancy (55,56), these findings in pregnant women in Africa indicate higher concentrations than in other populations. Furthermore, a study in the USA reported that while median CRP was 4.8 mg/l during pregnancy, black race was independently associated with serum CRP levels greater than the 75th percentile (15·7 mg/l)<sup>(57)</sup>. A systematic review has shown that race/ethnicity is independently associated with CRP concentrations, and that people of African, Latin or South Asian descent are at higher risk for elevated CRP<sup>(58)</sup>. Thus, the high prevalence of elevated CRP concentration in our pregnant, black African population is potentially partly due to effects of physiological state and race in addition to the influence of infection/inflammation.

Over two-thirds of the women with anaemia also had raised AGP and/or CRP. Over two-thirds of the anaemic women were not Fe-deficient on the basis of either ferritin  $<30 \mu g/l$ , adjusted ferritin  $<12 \mu g/l$  or sTfR  $>8.3 \mu g/l$ . Furthermore, more than half of the anaemic women who did not have ID based on the indicators used in the study had raised AGP and/or CRP. In Malawi, 73.5% of anaemic pregnant women who were Fe-replete by bone marrow assessment had raised CRP(7). Another study in Côte d'Ivoire found that IDA accounted for only ~50% of anaemia in non-pregnant women and adult men<sup>(59)</sup>. We also found that the PAR of CRP for anaemia was 41 %. In other words, 41% of anaemia in our population would not have occurred if CRP levels were normal (reflecting absence of infection/inflammation). These findings highlight the significant role of infection/inflammation in

<sup>†</sup>Variables in the analysis: *H. pylori* status, malaria status, hookworm, CRP status. Fe status using sTfR > 8·3 µg/ml.

<sup>‡</sup>Variables in the analysis: H. pylori status, malaria status, hookworm, CRP status, Fe status using adjusted ferritin <12 µg/l.

anaemia in our setting, implying that infection/inflammation should be considered in the strategies currently being used to control and prevent anaemia.

Only eight (5.3%) women had malaria parasites, a finding which is consistent with the Uganda Malaria Indicator Survey of 2009<sup>(17)</sup>. In spite of the low prevalence, malaria was independently associated with anaemia, albeit with a wide confidence interval. Only four women (2.7%) tested positive for syphilis at enrolment, which was unexpectedly low for this community. However, the recently released AIDS Indicator Survey reported a low prevalence of syphilis in pregnant women (2.4%) and in women of child-bearing age (1.8%) in Uganda. (18) Hookworm infestation was also low at 5%, which is surprising as overcrowding and limited access to adequate water and sanitation are characteristic of the Kawempe area. Available data for Uganda indicate substantially higher rates of hookworm infestation in different settings (36,60-62). The atlas of human helminths in East Africa reports that at 6.5 %, the Central Region has the lowest prevalence of hookworm infestation in Uganda<sup>(19)</sup>. Ruralurban differences could account for the low prevalence we found as lower prevalence of hookworm infestation has been demonstrated in urban areas compared with rural areas<sup>(63–65)</sup>, although contradictory data have been reported from Zanzibar<sup>(66)</sup>. It is also possible that the prevalence of hookworm ova was underestimated in our study because only one stool sample was examined per participant. If the intensity of infection is low this may lead to false negative results due to sparse and unequal distribution of hookworm ova in stools and variation in the excretion of ova across days (67,68). This may account for the absence of an independent association between hookworm infestation and anaemia in our study.

The prevalence of *H. pylori* infection, based on the stool antigen test, was 70·2 %. A survey to provide background information to the current study found a prevalence of 45·4 % in pregnant women attending antenatal care in five districts in Uganda and 60·5 % among women enrolled at KHC (RK Baingana, unpublished results). Other data on the prevalence of *H. pylori* infection in Uganda are from children aged 12 years and below<sup>(69,70)</sup> and from patients referred for endoscopy<sup>(71)</sup> or who had cancer and benign tumours<sup>(72)</sup>, and are not representative of the general population. Our findings are consistent with data from Africa and other developing country settings<sup>(73)</sup>.

On the basis of case studies, observational studies and interventional trials in children and non-pregnant adolescents and adults, it has been suggested that *H. pylori* infection has a role in the aetiology of anaemia. A retrospective study in Germany found that after adjusting for multiple covariates, mean Hb at the beginning of pregnancy was lower among *H. pylori*-infected women than among uninfected women<sup>(13)</sup>. Anaemic, pregnant women in Turkey were *H. pylori*-positive<sup>(12)</sup> while pregnant women with severe anaemia in Zanzibar had nearly eightfold higher odds of *H. pylori* infection compared with women without

severe anaemia<sup>(11)</sup>. A randomized controlled pilot trial of *H. pylori* therapy in pregnant women with IDA in India showed that *H. pylori* eradication resulted in a significantly better response to Fe supplementation<sup>(14)</sup>. However, we did not find evidence of an association between *H. pylori* infection and anaemia. The relationship between *H. pylori* infection and anaemia may be influenced by the degree of anaemia and by the relative contribution ID makes to anaemia in the population under study<sup>(74)</sup>. This probably accounts for our finding because women with severe anaemia were not included in our study and IDA comprised only a small proportion of anaemia in our study population.

A limitation of our study is that we did not explore other dietary factors associated with anaemia such as vitamin A, vitamin B<sub>12</sub> and folate deficiency. The prevalence of vitamin A deficiency among women in Kampala in 2006 was 14 %<sup>(75)</sup> and 47 % of women had inadequate usual intakes of vitamin  $A^{(76)}$ . Data on the prevalence of folate and vitamin B<sub>12</sub> deficiencies are scanty; however, 7% and 64% of women in Kampala had inadequate usual intakes<sup>(76)</sup> of the two micronutrients, respectively. A study in young adults in Kampala<sup>(77)</sup> and another in older adults in a rural setting<sup>(78)</sup> found that folate deficiency was not common. Future studies need to consider vitamin A and vitamin B<sub>12</sub> deficiencies. A second limitation of the study is that we were not able to assess gestational age by ultrasonography, which is considered the gold standard before 20 weeks' gestation. Hoffman et al. (79) suggest that gestational age dating using the last menstrual period collected early in pregnancy approximates reasonably to the gestational age obtained from first-trimester ultrasound given the shorter period of time over which the woman has to recall. Our participants presented themselves for antenatal care early during pregnancy (as opposed to during the second or third trimesters which is the norm in our setting), thus there is reason to believe that their recall was fairly accurate. Moreover, the last menstrual period tends to overestimate the true gestational age<sup>(79,80)</sup> and thus it is not likely that the women were over 16 weeks' gestational age.

## Conclusion

In conclusion, infections and/or inflammation, defined as elevated CRP or AGP concentrations, are important in the aetiology of anaemia in pregnant women during the first trimester in our setting. Public health measures to control infections and inflammation are urgently needed, in particular during pregnancy, as part of the anaemia control package. Considering that pregnancy triggers a state of inflammation and that CRP concentrations vary by race, there is a need to develop CRP reference values in normal, healthy African pregnant women in order to facilitate the interpretation of ferritin and other factors that are influenced by the acute-phase response. Further studies of the regulation of hepcidin in pregnancy in the

presence of infection and/or inflammation are necessary in order to broaden our understanding of the overall regulation of Fe metabolism.

### Acknowledgements

Acknowledgements: The women who took part in this study are gratefully acknowledged. The support of the Management, Kawempe Health Centre, the staff of the antenatal care clinic and of the laboratory, particularly Andrew Bamulumbye, is sincerely appreciated. The authors thank Pross Nammande for research assistance during data collection, Erwin Wiegerinck for the measurements of serum hepcidin and Levi Mugenyi for carrying out the data analysis. Financial support: This work was supported by Nutricia Research Foundation (grant number 2008-08) and a PhD Fellowship to R.K.B. from Innovations @ Makerere Committee. The funders had no role in the design, analysis or writing of this article. Conflict of interest: None. Authorship: R.K.B., J.K.E. and L.D. designed the study. R.K.B. collected and entered data and carried out laboratory analyses for ferritin, transferrin receptor, CRP, AGP and H. pylori. H.T. and D.W.S. were responsible for hepcidin analysis and interpretation of results. R.K.B. drafted the manuscript. All others reviewed the drafts and gave final approval for submission. Ethics of human subject participation: The study was approved by Makerere University Faculty of Medicine Research and Ethics Committee and was registered with the Uganda National Council for Science and Technology.

## References

- World Health Organization (2008) Worldwide Prevalence of Anaemia 1993–2005: WHO Global Database on Anaemia. Geneva: WHO.
- Government of Uganda (2013) Annual Health Sector Performance Report Financial Year 2012/2013. Kampala: Ministry of Health.
- 3. Uganda Bureau of Statistics & ICF International Inc. (2012) *Uganda Demographic and Health Survey 2011*. Kampala and Calverton, MD: UBOS and ICF International Inc.
- Gerbens-Leenes PW, Nonhebel S & Krol MS (2010) Food consumption patterns and economic growth. Increasing affluence and the use of natural resources. *Appetite* 55, 597–608.
- Lee SE, Talegawkar SA, Merialdi M et al. (2013) Dietary intakes of women during pregnancy in low- and middleincome countries. Public Health Nutr 16, 1340–1353.
- Balarajan Y, Ramakrishnan U, Ozaltin E et al. (2011) Anaemia in low-income and middle-income countries. Lancet 378, 2123–2135.
- van den Broek NR & Letsky EA (2000) Etiology of anemia in pregnancy in south Malawi. Am J Clin Nutr 72, 1 Suppl., 2478–56S.
- 8. Hinderaker SG, Olsen BE, Lie RT *et al.* (2002) Anemia in pregnancy in rural Tanzania: associations with micronutrients status and infections. *Eur J Clin Nutr* **56**, 192–199.
- Yuan W, Li Y, Yang K et al. (2010) Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 45, 665–676.

- Qu XH, Huang XL, Xiong P et al. (2010) Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World I Gastroenterol 16, 886–896.
- Farag TH, Stoltzfus RJ, Khalfan SS et al. (2007) Helicobacter pylori infection is associated with severe anemia of pregnancy on Pemba Island, Zanzibar. Am J Trop Med Hyg 76, 541–548.
- Mulayim B, Celik NY & Yanik FF (2008) Helicobacter pylori infection detected by <sup>14</sup>C-urea breath test is associated with iron deficiency anemia in pregnant women. J Obstet Gynaecol Res 34, 980–985.
- Weyermann M, Rothenbacher D, Gayer L et al. (2005) Role of Helicobacter pylori infection in iron deficiency during pregnancy. Am J Obstet Gynecol 192, 548–553.
- Malik R, Guleria K, Kaur I et al. (2011) Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy – a pilot study. Indian J Med Res 134, 224–231.
- Drakesmith H & Prentice AM (2012) Hepcidin and the iron-infection axis. Science 338, 768–772.
- Ganz T & Nemeth E (2012) Hepcidin and iron homeostasis. Biochim Biophys Acta 1823, 1434–1443.
- Uganda Bureau of Statistics & ICF Macro (2010) Uganda Malaria Indicator Survey 2009. Kampala and Calverton, MD: UBOS and ICF Macro.
- Ministry of Health (Uganda), ICF International, Centers for Disease Control and Prevention (Uganda), US Agency for International Development (Uganda) & WHO (Uganda) (2012) Uganda AIDS Indicator Survey 2011. Kampala/ Calverton, MD/Entebbe/Kampala/Kampala: Ministry of Health/ ICF International/Centers for Disease Control and Prevention/ USAID/WHO Uganda.
- 19. Brooker S, Kabatereine NB, Smith JL *et al.* (2009) An updated atlas of human helminth infections: the example of East Africa. *Int J Health Geogr* **8**, 42.
- Ministry of Health (Uganda) (2002) National Anemia Policy. Kampala: Ministry of Health.
- Ministry of Health (Uganda) (2005) Uganda National Policy Guidelines for HIV Counselling and Testing. Kampala: Ministry of Health.
- Nestel P (2002) Adjusting Hemoglobin Values in Program Surveys. Washington, DC: International Nutritional Anemia Consultative Group.
- 23. World Health Organization (1994) Bench Aids for the Diagnosis of Intestinal Parasites. Geneva: WHO.
- Malfertheiner P, Megraud F, O'Morain C et al. (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772–781.
- Laarakkers CM, Wiegerinck ET, Klaver S et al. (2013) Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform. PLoS One 8, e75518.
- Kroot JJ, Laarakkers CM, Geurts-Moespot AJ et al. (2010) Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 56, 1570–1579.
- Swinkels DW, Girelli D, Laarakkers C et al. (2008) Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One 3, e2706.
- Filmer D & Pritchett LH (2001) Estimating wealth effects without expenditure data – or tears: an application to educational enrollments in states of India. *Demography* 38, 115–132.
- Vyas S & Kumaranayake L (2006) Constructing socioeconomic status indices: how to use principal components analysis. *Health Policy Plan* 21, 459–468.
- Knabl J, Riedel C, Gmach J et al. (2014) Prediction of excessive gestational weight gain from week-specific cutoff values: a cohort study. J Perinatol 34, 351–356.
- World Health Organization (1995) Maternal anthropometry and pregnancy outcomes: a WHO collaborative study. *Bull* World Health Organ 73, Suppl., 1–6.

32. World Health Organization & Centers for Disease Control and Prevention (2007) Report of a Joint World Health Organization/Centers for Disease Control and Prevention Technical Consultation on the Assessment of Iron Status at the Population Level, 2nd ed. Geneva: WHO.

1434

- Van Den Broek NR, Letsky EA, White SA et al. (1998) Iron status in pregnant women: which measurements are valid? Br J Haematol 103, 817–824.
- Thurnham DI, McCabe LD, Haldar S et al. (2010) Adjusting plasma ferritin concentrations to remove the effects of subclinical inflammation in the assessment of iron deficiency: a meta-analysis. Am J Clin Nutr 92, 546–555.
- Flynn MR (2010) Analysis of censored exposure data by constrained maximization of the Shapiro–Wilk W statistic. Ann Occup Hyg 54, 263–271.
- Ndyomugyenyi R, Kabatereine N, Olsen A et al. (2008)
   Malaria and hookworm infections in relation to haemoglobin and serum ferritin levels in pregnancy in Masindi district,
   western Uganda. Trans R Soc Trop Med Hyg 102, 130–136.
- 37. Ndyomugyenyi R & Magnussen P (2000) Chloroquine prophylaxis, iron–folic acid supplementation or case management of malaria attacks in primigravidae in western Uganda: effects on maternal parasitaemia and haemoglobin levels and on birthweight. *Trans R Soc Trop Med Hyg* 94, 413–418.
- Namusoke F, Rasti N, Kironde F et al. (2010) Malaria burden in pregnancy at Mulago national referral hospital in Kampala, Uganda. Malar Res Treat 2010, 913857.
- 39. Ndibazza J, Muhangi L, Akishule D *et al.* (2010) Effects of deworming during pregnancy on maternal and perinatal outcomes in Entebbe, Uganda: a randomized controlled trial. *Clin Infect Dis* 50, 531–540.
- Akesson A, Bjellerup P, Berglund M et al. (1998) Serum transferrin receptor: a specific marker of iron deficiency in pregnancy. Am J Clin Nutr 68, 1241–1246.
- Thorpe SJ, Heath A, Sharp G et al. (2010) A WHO reference reagent for the serum transferrin receptor (sTfR): international collaborative study to evaluate a recombinant soluble transferrin receptor preparation. Clin Chem Lab Med 48, 815–820.
- Akesson A, Bjellerup P, Berglund M et al. (2002) Soluble transferrin receptor: longitudinal assessment from pregnancy to postlactation. Obstet Gynecol 99, 260–266.
- Huddle JM, Gibson RS & Cullinan TR (1999) The impact of malarial infection and diet on the anaemia status of rural pregnant Malawian women. Eur J Clin Nutr 53, 792–801.
- Hyder SM, Persson LA, Chowdhury M et al. (2004) Anaemia and iron deficiency during pregnancy in rural Bangladesh. Public Health Nutr 7, 1065–1070.
- Schulze KJ, Christian P, Ruczinski I et al. (2008) Hepcidin and iron status among pregnant women in Bangladesh. Asia Pac J Clin Nutr 17, 451–456.
- Ferguson BJ, Skikne BS, Simpson KM et al. (1992) Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med 119, 385–390.
- Verhoef H, West CE, Ndeto P et al. (2001) Serum transferrin receptor concentration indicates increased erythropoiesis in Kenyan children with asymptomatic malaria. Am J Clin Nutr 74, 767–775.
- Menendez C, Quinto LL, Kahigwa E et al. (2001) Effect of malaria on soluble transferrin receptor levels in Tanzanian infants. Am J Trop Med Hyg 65, 138–142.
- Righetti AA, Wegmuller R, Glinz D et al. (2013) Effects of inflammation and *Plasmodium falciparum* infection on soluble transferrin receptor and plasma ferritin concentration in different age groups: a prospective longitudinal study in Cote d'Ivoire. *Am J Clin Nutr* 97, 1364–1374.
- Williams TN, Maitland K, Rees DC et al. (1999) Reduced soluble transferrin receptor concentrations in acute malaria in Vanuatu. Am J Trop Med Hyg 60, 875–878.

- 51. van Santen S, Kroot JJ, Zijderveld G *et al.* (2013) The iron regulatory hormone hepcidin is decreased in pregnancy: a prospective longitudinal study. *Clin Chem Lab Med* **51**, 1395–1401.
- Galesloot TE, Vermeulen SH, Geurts-Moespot AJ et al. (2011) Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 117, e218–e225.
- 53. Simavli S, Uysal A, Uysal DS *et al.* (2014) Hepcidin, iron status, and inflammation variables among healthy pregnant women in the Turkish population. *J Matern Fetal Neonatal Med* **27**, 75–79.
- 54. Kroot JJ, Tjalsma H, Fleming RE *et al.* (2011) Hepcidin in human iron disorders: diagnostic implications. *Clin Chem* **57**, 1650–1669.
- Teran E, Escudero C & Calle A (2005) C-reactive protein during normal pregnancy and preeclampsia. *Int J Gynaecol Obstet* 89, 299–300.
- Larsson A, Palm M, Hansson LO et al. (2008) Reference values for α1-acid glycoprotein, α1-antitrypsin, albumin, haptoglobin, C-reactive protein, IgA, IgG and IgM during pregnancy. Acta Obstet Gynecol Scand 87, 1084–1088.
- Picklesimer AH, Jared HL, Moss K et al. (2008) Racial differences in C-reactive protein levels during normal pregnancy. Am J Obstet Gynecol 199, 523.e1–e6.
- Nazmi A & Victora CG (2007) Socioeconomic and racial/ ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. *BMC Public Health* 7, 212.
- Asobayire FS, Adou P, Davidsson L et al. (2001) Prevalence of iron deficiency with and without concurrent anemia in population groups with high prevalences of malaria and other infections: a study in Cote d'Ivoire. Am J Clin Nutr 74, 776–782.
- Muhangi L, Woodburn P, Omara M et al. (2007) Associations between mild-to-moderate anaemia in pregnancy and helminth, malaria and HIV infection in Entebbe, Uganda. Trans R Soc Trop Med Hyg 101, 899–907.
- 61. Pullan RL, Kabatereine NB, Bukirwa H *et al.* (2010) Heterogeneities and consequences of *Plasmodium* species and hookworm coinfection: a population based study in Uganda. *J Infect Dis* **203**, 406–417.
- 62. Shapiro AE, Tukahebwa EM, Kasten J *et al.* (2005) Epidemiology of helminth infections and their relationship to clinical malaria in southwest Uganda. *Trans R Soc Trop Med Hyg* **99**, 18–24.
- 63. Ayoya MA, Spiekermann-Brouwer GM, Traore AK *et al.* (2006) Determinants of anemia among pregnant women in Mali. *Food Nutr Bull* **27**, 3–11.
- 64. Mbuh JV, Ntonifor NH & Ojong J (2012) The epidemiology of soil-transmitted helminth and protozoan infections in south-west Cameroon. *J Helminthol* **86**, 30–37.
- Oninla SO, Owa JA, Onayade AA et al. (2007) Intestinal helminthiases among rural and urban schoolchildren in southwestern Nigeria. Ann Trop Med Parasitol 101, 705–713.
- 66. Knopp S, Mohammed KA, Stothard JR et al. (2010) Patterns and risk factors of helminthiasis and anemia in a rural and a peri-urban community in Zanzibar, in the context of helminth control programs. PLoS Negl Trop Dis 4, e681.
- 67. Knopp S, Mgeni AF, Khamis IS *et al.* (2008) Diagnosis of soil-transmitted helminths in the era of preventive chemotherapy: effect of multiple stool sampling and use of different diagnostic techniques. *PLoS Negl Trop Dis* **2**, e331.
- 68. Goodman D, Haji HJ, Bickle QD et al. (2007) A comparison of methods for detecting the eggs of Ascaris, Trichuris, and hookworm in infant stool, and the epidemiology of infection in Zanzibari infants. Am J Trop Med Hyg 76, 725–731.
- Gupta V, Perez-Perez GI, Dorsey G et al. (2012) The seroprevalence of Helicobacter pylori and its relationship to malaria in Ugandan children. Trans R Soc Trop Hyg 106, 35–42.

- Hestvik E, Tylleskar T, Kaddu-Mulindwa DH et al. (2010) Helicobacter pylori in apparently healthy children aged 0–12 years in urban Kampala, Uganda: a community-based cross sectional survey. BMC Gastroenterol 10, 62.
- Ochama P (2001) Testing for Helicobacter pylori status in patients undergoing diagnostic endoscopy in Mulago and Nsambya hospitals. MMed Dissertation, Makerere University.
- 72. Newton R, Ziegler JL, Casabonne D *et al.* (2006) *Helico-bacter pylori* and cancer among adults in Uganda. *Infect Agent Cancer* 1, 5.
- Goh KL, Chan WK, Shiota S et al. (2011) Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 16, Suppl. 1, 1–9.
- Figura N, Franceschi F, Santucci A et al. (2010) Extragastric manifestations of Helicobacter pylori infection. Helicobacter 15, Suppl. 1, 60–68.
- Uganda Bureau of Statistics & Macro International Inc.
   (2007) Uganda Demographic and Health Survey 2006.
   Calverton, MD: UBOS and Macro International Inc.

- Harvey P, Rambeloson Z & Dary O (2010) The 2008 Uganda Food Consumption Survey: Determining the Dietary Patterns of Ugandan Women and Children. Washington, DC: A2Z: The USAID Micronutrient and Child Blindness Project, AED.
- Galukande M, Jombwe J, Fualal J et al. (2011) Reference values for serum levels of folic acid and vitamin B<sub>12</sub> in a young adult Ugandan population. Afr Health Sci 11, 240–243.
- Mugisha JO, Baisley K, Asiki G et al. (2013) Prevalence, types, risk factors and clinical correlates of anaemia in older people in a rural Ugandan population. PLoS One 8, e78394.
- Hoffman CS, Messer LC, Mendola P et al. (2008) Comparison of gestational age at birth based on last menstrual period and ultrasound during the first trimester. Paediatr Perinat Epidemiol 22, 587–596.
- Geerts L, Poggenpoel E & Theron G (2013) A comparison of pregnancy dating methods commonly used in South Africa: a prospective study. S Afr Med J 103, 552–556.